Healthcare / Health Information ServicesNasdaqGM
$2.17
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 22%
FCF escenarios
weak_data · normalized FCF $653325.00 · quality 45.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
40/100
C
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$68M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-9.7%
↓Gross Margin
53.2%
↑Debt/Equity
0.00
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2019–2025 · 6 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
9.5%
FCF / Net income
-1.00x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $30.3M · net income $-2.9M · FCF $2.9M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | $30.3M | $30.3M | $20.2M | $21.2M | $16.4M | $16.9M | $544871.00 | — |
| Net Income | $-2.9M | $-2.9M | $-3.8M | $11.8M | $-26.0M | $-26.6M | $-5.0M | — |
| EBITDA | $-2.3M | $-2.3M | $-2.9M | $3.4M | $-18.3M | $-25.6M | $-5.0M | — |
| EPS | -0.09 | -0.09 | -0.12 | 0.34 | -0.81 | -0.90 | -0.38 | — |
| Gross Margin | 53.2% | 53.2% | 63.6% | 74.2% | 69.2% | — | 93.0% | — |
| Operating Margin | -8.2% | -8.2% | -27.6% | -15.6% | -82.4% | -163.6% | -914.7% | — |
| Net Margin | -9.5% | -9.5% | -18.7% | 55.5% | -158.2% | -157.3% | -914.0% | — |
| Balance Sheet | ||||||||
| Debt/Equity | 0.00 | 0.00 | 0.22 | 0.90 | 2.02 | — | — | — |
| Current Ratio | 3.14 | 3.14 | — | — | — | — | — | — |
| Cash Flow | ||||||||
| Free Cash Flow | $2.9M | $2.9M | $282827.00 | $653325.00 | $-8.6M | $-18.7M | $-4.3M | — |
| Returns | ||||||||
| ROE | -9.7% | -9.7% | -12.5% | 42.5% | -209.1% | -105.5% | -44.2% | — |
| Valuation | ||||||||
| P/E | — | — | — | 7.47 | — | — | — | — |
| EV/EBITDA | — | — | — | 29.51 | — | — | — | — |
| P/B | 2.27 | 2.27 | 2.14 | 2.95 | 6.38 | — | — | — |
| Growth & Yield | ||||||||
| Revenue Growth | 50.1% | 50.1% | -5.0% | 29.2% | — | 2997.9% | — | — |
| EPS Growth | 25.0% | 25.0% | -135.3% | 142.0% | — | -136.8% | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-3.1%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.12 → -0.09
Residual
-3.1%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.